Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 4/20 | 0.43 |
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CPT2 | P23786 | 2/20 | 0.40 |
| ▸ | CPT1A | P50416 | 2/20 | 0.40 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000215 | 0.88 | NPC1 (0.43) | MAPTSMN1; SMN2CNR2CNR1TP53 | |
| SCHEMBL2002470 | 0.87 | MAPT (0.45) | MAPTSMN1; SMN2CNR2TP53MEN1 | |
| SCHEMBL2004861 | 0.84 | CNR1 (0.43) | MAPTCNR2CNR1TP53MEN1 | |
| SCHEMBL1998982 | 0.84 | CNR1 (0.43) | MAPTCNR2CNR1TP53MEN1 | |
| SCHEMBL4050862 | 0.84 | CNR1 (0.43) | MAPTCNR2CNR1TP53MEN1 | |
| SCHEMBL2002323 | 0.84 | MCL1 (0.47) | MAPTSMN1; SMN2CNR2CNR1TP53 | |
| SCHEMBL1998986 | 0.83 | CYP2C9 (0.48) | MAPTSMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL1999363 | 0.82 | CPT2 (0.41) | MAPTSMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL2004860 | 0.82 | MAPT (0.40) | MAPTSMN1; SMN2TP53MEN1KMT2A | |
| SCHEMBL4056358 | 0.82 | MAPT (0.40) | MAPTSMN1; SMN2TP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960376-B2 | Benzo-fused heterocycles | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075973-A1 | BENZO-FUSED HETEROCYCLES | CNR1, CNR2, TRPV1 | MAPT 1743/4885SMN1; SMN2 3964/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.